{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:42:32Z","timestamp":1793277752274,"version":"4.5.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Atrial fibrillation (AF) commonly coexists with hypertrophic obstructive cardiomyopathy (HOCM) and is associated with increased risks of stroke and mortality. While catheter ablation (CA) is effective in AF, outcomes in patients with HOCM remain underreported. We sought to evaluate the association between CA and long-term outcomes in patients with paroxysmal AF (PAF) and HOCM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Using the TriNetX Research Network, we identified adults (\u226518 years) diagnosed with HOCM and PAF between 2015 and 2021. Patients were stratified into CA vs. non-CA groups. Propensity score matching (1:1) was used to adjust for differences in demographics, comorbidities, and medications. The primary outcome was all-cause mortality and ischemic stroke at 3 years; secondary outcomes included cardioversion and new-onset heart failure. Kaplan-Meier analysis and Cox proportional hazards regression were used to estimate adjusted hazard ratios (HRs). Among 8593 patients with HOCM and PAF, 1018 (11.8%) underwent CA. Post-PSM, 966 patients were matched per group. All-cause mortality was markedly reduced in the CA group (4.9% vs. 13.7%, HR: 0.35, 95% CI: 0.25\u20130.49, P &amp;lt; 0.0001). Ischemic stroke rates were significantly lower in the CA group (6.4% vs. 9.7%, HR: 0.63, 95% CI: 0.46\u20130.87, P &amp;lt; 0.01), including among patients without prior stroke (de novo stroke: 3.7% vs. 5.7%, HR: 0.63, 95% CI: 0.40\u20130.98, P &amp;lt; 0.05). Cardioversion was significantly higher following CA (30.1% vs. 10.1%, HR: 3.2, 95% CI: 2.5\u20134.0, P &amp;lt; 0.0001). There was no significant difference in new-onset heart failure between the CA and non-CA groups (69.1% vs. 72.0%; HR: 1.08, 95% CI: 0.84\u20131.40, P = 0.53).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with HOCM and PAF, CA was associated with significantly lower risks of ischemic stroke and all-cause mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjqcco\/qcaf110","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:55:14Z","timestamp":1758369314000},"page":"107-115","source":"Crossref","is-referenced-by-count":3,"title":["Catheter ablation in patients with atrial fibrillation and hypertrophic obstructive cardiomyopathy: a real-world comparative outcomes study"],"prefix":"10.1093","volume":"12","author":[{"given":"Dharmindra","family":"Dulal","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Ohio State University Wexner Medical Center , Columbus, OH 43210 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Maraey","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of Toledo Medical Center , 3000 Arlington Ave., Toledo, OH 43614 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Younes","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Riverside Memorial Medical Center , Onancock, VA 23417 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Kahaly","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, ProMedica Toledo Hospital , Toledo, OH 43606 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Finlay","sequence":"additional","affiliation":[{"name":"Barts Health NHS Trust , London E14 5HJ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Maan","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of Toledo Medical Center , 3000 Arlington Ave., Toledo, OH 43614 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Kevin","family":"Heist","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School , Boston, MA 02114 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"2026010603572316700_qcaf110-B1","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.117.029267","article-title":"Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy","volume":"136","author":"Rowin","year":"2017","journal-title":"Circulation"},{"key":"2026010603572316700_qcaf110-B2","first-page":"1200","article-title":"Predictors of atrial fibrillation risk in hypertrophic cardiomyopathy","volume":"7","author":"Tuluce","year":"2015","journal-title":"J Atr Fibrillation"},{"key":"2026010603572316700_qcaf110-B3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study","volume":"386","author":"Schnabel","year":"2015","journal-title":"Lancet"},{"key":"2026010603572316700_qcaf110-B4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/CLEP.S47385","article-title":"Epidemiology of atrial fibrillation: European perspective","volume":"6","author":"Zoni-Berisso","year":"2014","journal-title":"Clin Epidemiol"},{"key":"2026010603572316700_qcaf110-B5","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/hc4601.097997","article-title":"Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy","volume":"104","author":"Olivotto","year":"2001","journal-title":"Circulation"},{"key":"2026010603572316700_qcaf110-B6","first-page":"e558","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"2026010603572316700_qcaf110-B7","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","article-title":"Hypertrophic cardiomyopathy","volume":"381","author":"Maron","year":"2013","journal-title":"Lancet"},{"key":"2026010603572316700_qcaf110-B8","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"2026010603572316700_qcaf110-B9","doi-asserted-by":"crossref","first-page":"101210","DOI":"10.1016\/j.jacadv.2024.101210","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy","volume":"3","author":"Weissler-Snir","year":"2024","journal-title":"JACC Adv"},{"key":"2026010603572316700_qcaf110-B10","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1056\/NEJMoa2306037","article-title":"Catheter ablation in end-stage heart failure with atrial fibrillation","volume":"389","author":"Sohns","year":"2023","journal-title":"N Engl J Med"},{"key":"2026010603572316700_qcaf110-B11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N Engl J Med"},{"key":"2026010603572316700_qcaf110-B12","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1161\/CIRCULATIONAHA.115.019406","article-title":"Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial","volume":"133","author":"Di Biase","year":"2016","journal-title":"Circulation"},{"key":"2026010603572316700_qcaf110-B13","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1540-8167.2008.01192.x","article-title":"Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy","volume":"19","author":"Bunch","year":"2008","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026010603572316700_qcaf110-B14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/europace\/euq013","article-title":"Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression","volume":"12","author":"Di Donna","year":"2010","journal-title":"Europace"},{"key":"2026010603572316700_qcaf110-B15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ehjqcco\/qcaf020","article-title":"Five-year outcomes following catheter ablation for paroxysmal atrial fibrillation: a propensity matched analysis of 51 182 patients from a real world cohort","volume":"12","author":"Maraey","year":"2026","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026010603572316700_qcaf110-B16","first-page":"e680","article-title":"Long-term outcomes of catheter ablation in dialysis patients with paroxysmal atrial fibrillation receiving anticoagulation: a propensity-matched analysis","volume":"22","author":"Dulal","year":"2025","journal-title":"Heart Rhythm"},{"key":"2026010603572316700_qcaf110-B17","doi-asserted-by":"crossref","first-page":"e001002","DOI":"10.1161\/JAHA.114.001002","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population","volume":"3","author":"Siontis","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2026010603572316700_qcaf110-B18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.21037\/cdt.2016.11.23","article-title":"Outcomes in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a survival meta-analysis","volume":"7","author":"Masri","year":"2017","journal-title":"Cardiovasc Diagn Ther"},{"key":"2026010603572316700_qcaf110-B19","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1161\/01.CIR.92.4.835","article-title":"Left atrial size and the risk of stroke and death","volume":"92","author":"Benjamin","year":"1995","journal-title":"Circulation"},{"key":"2026010603572316700_qcaf110-B20","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.jacc.2006.02.048","article-title":"Left atrial size: physiologic determinants and clinical applications","volume":"47","author":"Abhayaratna","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026010603572316700_qcaf110-B21","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/HYPERTENSIONAHA.114.03975","article-title":"Prognostic significance of left atrial enlargement in a general population: results of the PAMELA study","volume":"64","author":"Bombelli","year":"2014","journal-title":"Hypertension"},{"key":"2026010603572316700_qcaf110-B22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000354953","article-title":"Clinical profile and prognostic significance of atrial fibrillation in hypertrophic cardiomyopathy","volume":"126","author":"Tian","year":"2013","journal-title":"Cardiology"},{"key":"2026010603572316700_qcaf110-B23","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/heartjnl-2013-304276","article-title":"Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review","volume":"100","author":"Guttmann","year":"2014","journal-title":"Heart"},{"key":"2026010603572316700_qcaf110-B24","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1046\/j.1540-8167.2002.00954.x","article-title":"Atrial fibrillation precipitating sustained ventricular tachycardia in hypertrophic cardiomyopathy","volume":"13","author":"Boriani","year":"2002","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026010603572316700_qcaf110-B25","first-page":"509","article-title":"The role of atrial structural remodeling in atrial fibrillation ablation:an imaging point of view for predicting recurrence","volume":"5","author":"Akutsu","year":"2012","journal-title":"J Atr Fibrillation"},{"key":"2026010603572316700_qcaf110-B26","first-page":"877","article-title":"Cardiac remodeling after atrial fibrillation ablation","volume":"6","author":"Lo","year":"2013","journal-title":"J Atr Fibrillation"},{"key":"2026010603572316700_qcaf110-B27","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1093\/eurheartj\/ehw087","article-title":"Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries","volume":"37","author":"Friberg","year":"2016","journal-title":"Eur Heart J"},{"key":"2026010603572316700_qcaf110-B28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijcard.2018.03.068","article-title":"Association of catheter ablation for atrial fibrillation with mortality and stroke: a systematic review and meta-analysis","volume":"266","author":"Barra","year":"2018","journal-title":"Int J Cardiol"}],"container-title":["European Heart Journal - Quality of Care and Clinical Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjqcco\/advance-article-pdf\/doi\/10.1093\/ehjqcco\/qcaf110\/64416301\/qcaf110.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/12\/1\/107\/64416301\/qcaf110.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/12\/1\/107\/64416301\/qcaf110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:57:30Z","timestamp":1767689850000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article\/12\/1\/107\/8266582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,9,26]]},"published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjqcco\/qcaf110","relation":{},"ISSN":["2058-5225","2058-1742"],"issn-type":[{"value":"2058-5225","type":"print"},{"value":"2058-1742","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,9,26]]}}}